Good company judging by the company's performance and stock trend. Rolled back to the area 30% on the news about the vaccine Quarterly reporting will be February 2, 2021. If vaccination does not show significant benefits and the company's revenues continue to grow, it is possible that the shares will be bought back.
What do you think about the shares of this company?
Transaction en cours
Consolidation is broken upwards.
Note
Option Finder:
Long Call: Buy 1x 15th Oct $590,00 Call @ $4,10 Entry cost: $410,00 (debit) Maximum risk1: $410,00 Est. return1 at target price: $3 590,00 (875.6%)
Les informations et les publications ne sont pas destinées à être, et ne constituent pas, des conseils ou des recommandations en matière de finance, d'investissement, de trading ou d'autres types de conseils fournis ou approuvés par TradingView. Pour en savoir plus, consultez les Conditions d'utilisation.